Literature DB >> 10978191

Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design.

C L Moore1, D D Leatherwood, T S Diehl, D J Selkoe, M S Wolfe.   

Abstract

The final step in the generation of the amyloid-beta protein (Abeta), implicated in the etiology of Alzheimer's disease, is proteolysis within the transmembrane region of the amyloid precursor protein (APP) by gamma-secretase. Although considered an important target for therapeutic design, gamma-secretase has been neither well-characterized nor definitively identified. Previous studies in our laboratory using substrate-based difluoro ketone and difluoro alcohol transition-state analogue inhibitors suggest that gamma-secretase is an aspartyl protease with loose sequence specificity. To further characterize the active site of gamma-secretase, we prepared a series of difluoro ketone peptide analogues with varying steric bulkiness in the P1 position and tested the ability of these compounds to inhibit Abeta production in APP-transfected cells. Incorporation of bulky, aliphatic P1 side chains, such as sec-butyl or cyclohexylmethyl, led to increased gamma-secretase inhibitory potency, suggesting a large S1 pocket to accommodate these substituents and providing further evidence for loose sequence specificity. The cyclohexylmethyl P1 substituent allowed N-terminal truncation to a low-molecular-weight compound (<600 Da) that effectively blocked Abeta production (IC(50) approximately 5 microM). This finding suggests that optimal S1 binding may allow the development of potent inhibitors with ideal pharmaceutical properties. Moreover, a difluoro alcohol analogue with a cyclohexylmethyl P1 substituent was equipotent with its difluoro ketone counterpart, providing strong evidence that gamma-secretase is an aspartyl protease. All new analogues inhibited total Abeta and Abeta(42) production with the same rank order of potency and increased Abeta(42) production at low concentrations, providing further evidence for distinct gamma-secretases that are nevertheless closely similar with respect to active site topology and mechanism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10978191     DOI: 10.1021/jm000100f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Agonists of the γ-aminobutyric acid type B (GABAB) receptor derived from β-hydroxy and β-amino difluoromethyl ketones.

Authors:  Munia F Sowaileh; Amy E Salyer; Kuldeep K Roy; Jinu P John; James R Woods; Robert J Doerksen; Gregory H Hockerman; David A Colby
Journal:  Bioorg Med Chem Lett       Date:  2018-04-07       Impact factor: 2.823

2.  Transmembrane Substrate Determinants for γ-Secretase Processing of APP CTFβ.

Authors:  Marty A Fernandez; Kelly M Biette; Georgia Dolios; Divya Seth; Rong Wang; Michael S Wolfe
Journal:  Biochemistry       Date:  2016-09-30       Impact factor: 3.162

3.  Structure and Function of the γ-Secretase Complex.

Authors:  Michael S Wolfe
Journal:  Biochemistry       Date:  2019-06-25       Impact factor: 3.162

Review 4.  gamma-Secretase inhibitors as molecular probes of presenilin function.

Authors:  M S Wolfe
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 5.  Toward the structure of presenilin/γ-secretase and presenilin homologs.

Authors:  Michael S Wolfe
Journal:  Biochim Biophys Acta       Date:  2013-12

Review 6.  BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.

Authors:  Neville Marks; Martin J Berg
Journal:  Neurochem Res       Date:  2009-09-17       Impact factor: 3.996

7.  Continuing strategies for inhibiting Alzheimer's gamma-secretase.

Authors:  Michael S Wolfe; William P Esler; Chittaranjan Das
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

8.  Cyclohexyl ketone inhibitors of Pin1 dock in a trans-diaxial cyclohexane conformation.

Authors:  Guoyan G Xu; Carla Slebodnick; Felicia A Etzkorn
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 9.  Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer's Disease.

Authors:  Michael S Wolfe
Journal:  Molecules       Date:  2021-01-13       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.